Report cover image

Global Bupivacaine Liposome Injection Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 190 Pages
SKU # APRC20279000

Description

Summary

According to APO Research, the global Bupivacaine Liposome Injection market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Bupivacaine Liposome Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Bupivacaine Liposome Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Bupivacaine Liposome Injection market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Bupivacaine Liposome Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Bupivacaine Liposome Injection market include Pacira Pharmaceuticals and Jiangsu Hengrui Pharma etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Bupivacaine Liposome Injection, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Bupivacaine Liposome Injection, also provides the sales of main regions and countries. Of the upcoming market potential for Bupivacaine Liposome Injection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Bupivacaine Liposome Injection sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Bupivacaine Liposome Injection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Bupivacaine Liposome Injection sales, projected growth trends, production technology, application and end-user industry.


Bupivacaine Liposome Injection Segment by Company


Pacira Pharmaceuticals

Jiangsu Hengrui Pharma

Bupivacaine Liposome Injection Segment by Type


133mg per Vial

266mg per Vial

Bupivacaine Liposome Injection Segment by Application


Local Anesthesia

Postoperative Analgesia

Other

Bupivacaine Liposome Injection Segment by Region


North America


United States

Canada

Mexico

Europe


Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific


China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America


Brazil

Argentina

Chile

Colombia

Middle East & Africa


Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Bupivacaine Liposome Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Bupivacaine Liposome Injection market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Bupivacaine Liposome Injection significant trends, drivers, influence factors in global and regions.
6. To analyze Bupivacaine Liposome Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bupivacaine Liposome Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bupivacaine Liposome Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bupivacaine Liposome Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Bupivacaine Liposome Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Bupivacaine Liposome Injection industry.
Chapter 3: Detailed analysis of Bupivacaine Liposome Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Bupivacaine Liposome Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Bupivacaine Liposome Injection in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

190 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Bupivacaine Liposome Injection Sales Value (2020-2031)
1.2.2 Global Bupivacaine Liposome Injection Sales Volume (2020-2031)
1.2.3 Global Bupivacaine Liposome Injection Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Bupivacaine Liposome Injection Market Dynamics
2.1 Bupivacaine Liposome Injection Industry Trends
2.2 Bupivacaine Liposome Injection Industry Drivers
2.3 Bupivacaine Liposome Injection Industry Opportunities and Challenges
2.4 Bupivacaine Liposome Injection Industry Restraints
3 Bupivacaine Liposome Injection Market by Company
3.1 Global Bupivacaine Liposome Injection Company Revenue Ranking in 2024
3.2 Global Bupivacaine Liposome Injection Revenue by Company (2020-2025)
3.3 Global Bupivacaine Liposome Injection Sales Volume by Company (2020-2025)
3.4 Global Bupivacaine Liposome Injection Average Price by Company (2020-2025)
3.5 Global Bupivacaine Liposome Injection Company Ranking (2023-2025)
3.6 Global Bupivacaine Liposome Injection Company Manufacturing Base and Headquarters
3.7 Global Bupivacaine Liposome Injection Company Product Type and Application
3.8 Global Bupivacaine Liposome Injection Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Bupivacaine Liposome Injection Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Bupivacaine Liposome Injection Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Bupivacaine Liposome Injection Market by Type
4.1 Bupivacaine Liposome Injection Type Introduction
4.1.1 133mg per Vial
4.1.2 266mg per Vial
4.2 Global Bupivacaine Liposome Injection Sales Volume by Type
4.2.1 Global Bupivacaine Liposome Injection Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Bupivacaine Liposome Injection Sales Volume by Type (2020-2031)
4.2.3 Global Bupivacaine Liposome Injection Sales Volume Share by Type (2020-2031)
4.3 Global Bupivacaine Liposome Injection Sales Value by Type
4.3.1 Global Bupivacaine Liposome Injection Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Bupivacaine Liposome Injection Sales Value by Type (2020-2031)
4.3.3 Global Bupivacaine Liposome Injection Sales Value Share by Type (2020-2031)
5 Bupivacaine Liposome Injection Market by Application
5.1 Bupivacaine Liposome Injection Application Introduction
5.1.1 Local Anesthesia
5.1.2 Postoperative Analgesia
5.1.3 Other
5.2 Global Bupivacaine Liposome Injection Sales Volume by Application
5.2.1 Global Bupivacaine Liposome Injection Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Bupivacaine Liposome Injection Sales Volume by Application (2020-2031)
5.2.3 Global Bupivacaine Liposome Injection Sales Volume Share by Application (2020-2031)
5.3 Global Bupivacaine Liposome Injection Sales Value by Application
5.3.1 Global Bupivacaine Liposome Injection Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Bupivacaine Liposome Injection Sales Value by Application (2020-2031)
5.3.3 Global Bupivacaine Liposome Injection Sales Value Share by Application (2020-2031)
6 Bupivacaine Liposome Injection Regional Sales and Value Analysis
6.1 Global Bupivacaine Liposome Injection Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Bupivacaine Liposome Injection Sales by Region (2020-2031)
6.2.1 Global Bupivacaine Liposome Injection Sales by Region: 2020-2025
6.2.2 Global Bupivacaine Liposome Injection Sales by Region (2026-2031)
6.3 Global Bupivacaine Liposome Injection Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Bupivacaine Liposome Injection Sales Value by Region (2020-2031)
6.4.1 Global Bupivacaine Liposome Injection Sales Value by Region: 2020-2025
6.4.2 Global Bupivacaine Liposome Injection Sales Value by Region (2026-2031)
6.5 Global Bupivacaine Liposome Injection Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Bupivacaine Liposome Injection Sales Value (2020-2031)
6.6.2 North America Bupivacaine Liposome Injection Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Bupivacaine Liposome Injection Sales Value (2020-2031)
6.7.2 Europe Bupivacaine Liposome Injection Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Bupivacaine Liposome Injection Sales Value (2020-2031)
6.8.2 Asia-Pacific Bupivacaine Liposome Injection Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Bupivacaine Liposome Injection Sales Value (2020-2031)
6.9.2 South America Bupivacaine Liposome Injection Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Bupivacaine Liposome Injection Sales Value (2020-2031)
6.10.2 Middle East & Africa Bupivacaine Liposome Injection Sales Value Share by Country, 2024 VS 2031
7 Bupivacaine Liposome Injection Country-level Sales and Value Analysis
7.1 Global Bupivacaine Liposome Injection Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Bupivacaine Liposome Injection Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Bupivacaine Liposome Injection Sales by Country (2020-2031)
7.3.1 Global Bupivacaine Liposome Injection Sales by Country (2020-2025)
7.3.2 Global Bupivacaine Liposome Injection Sales by Country (2026-2031)
7.4 Global Bupivacaine Liposome Injection Sales Value by Country (2020-2031)
7.4.1 Global Bupivacaine Liposome Injection Sales Value by Country (2020-2025)
7.4.2 Global Bupivacaine Liposome Injection Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.5.2 USA Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.6.2 Canada Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.8.2 Germany Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.9.2 France Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.9.3 France Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.11.2 Italy Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.12.2 Spain Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.13.2 Russia Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.16.2 China Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.16.3 China Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.17.2 Japan Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.19.2 India Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.19.3 India Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.20.2 Australia Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.24.2 Chile Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.26.2 Peru Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.28.2 Israel Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.29.2 UAE Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.31.2 Iran Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Bupivacaine Liposome Injection Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Bupivacaine Liposome Injection Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Bupivacaine Liposome Injection Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Pacira Pharmaceuticals
8.1.1 Pacira Pharmaceuticals Comapny Information
8.1.2 Pacira Pharmaceuticals Business Overview
8.1.3 Pacira Pharmaceuticals Bupivacaine Liposome Injection Sales, Value and Gross Margin (2020-2025)
8.1.4 Pacira Pharmaceuticals Bupivacaine Liposome Injection Product Portfolio
8.1.5 Pacira Pharmaceuticals Recent Developments
8.2 Jiangsu Hengrui Pharma
8.2.1 Jiangsu Hengrui Pharma Comapny Information
8.2.2 Jiangsu Hengrui Pharma Business Overview
8.2.3 Jiangsu Hengrui Pharma Bupivacaine Liposome Injection Sales, Value and Gross Margin (2020-2025)
8.2.4 Jiangsu Hengrui Pharma Bupivacaine Liposome Injection Product Portfolio
8.2.5 Jiangsu Hengrui Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Bupivacaine Liposome Injection Value Chain Analysis
9.1.1 Bupivacaine Liposome Injection Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Bupivacaine Liposome Injection Sales Mode & Process
9.2 Bupivacaine Liposome Injection Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Bupivacaine Liposome Injection Distributors
9.2.3 Bupivacaine Liposome Injection Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.